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Abstract
The modified Friedreich Ataxia Rating Scale (mFARS) is a disease specific,
exam-based neurological rating scale commonly used as a outcome measure in
clinical trials. While extensive clinimetric testing indicates it’s validity in measuring disease progression, formal test–retest reliability was lacking. To fill this
gap, we acquired results from screening and baseline visits of several large clinical trials and calculated intraclass correlation coefficients, coefficients of variance, standard error, and the minimally detectable changes. This study
demonstrated excellent test–retest reliability of the mFARS, and it’s upright stability subscore.

Annals of Clinical and Translational
Neurology 2020; 7(9): 1708–1712
doi: 10.1002/acn3.51118

Introduction
Friedreich’s ataxia (FRDA) is a progressive, neurodegenerative disease that affects children and young adults with
gait and limb ataxia, dysarthria, loss of reflexes, proprioceptive dysfunction, and muscle weakness, as well as nonneurological features of cardiomyopathy, diabetes, and
scoliosis.1 FRDA is caused by a GAA repeat expansion in
the FXN gene,2 leading to a marked reduction in frataxin,
a mitochondrial protein that plays a vital role in energy
production and iron homeostasis.
While FRDA currently has no treatment or cure, novel
prospective therapeutic strategies are actively being studied in clinical trials, requiring the use of validated and
clinically meaningful outcome measures. One commonly
used disease specific measure Friedreich’s Ataxia Rating
Scale (FARS), an exam-based neurological measure. The
FARS was initially introduced in 2005.3 In addition to a
standardized neurological exam, its initial validation
1708

included in parallel a patient reported activities of daily
living scale (ADL), a functional disability staging (FDS),
and time-based performance measures. The initial version
of the neurological exam component of the FARS was
comprised of five subscores: bulbar (11 points), upper
limbs (36), lower limbs (16), peripheral nervous system
(26), and upright stability (28), summed for a total maximum score of 117 points.3 Later, two-timed stance items
without visual aid (standing with feet apart, eyes closed
and standing with feet together, eyes closed) were added
to the upright stability section, resulting in the FARSneuro (FARSn) with a total of 125 points.4 This version
has been used in multiple clinical trials as well as a
prospective, longitudinal natural history, and clinical outcome measures study (FA-COMS, NCT03090789) that
started in 2003.4 The FARSn has undergone further
refinement as a clinical outcome measure, omitting items
that do not directly assess functional abilities. Specifically,
the peripheral nervous system subscore and two bulbar
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components were removed, leading to the modified
FARS, or “mFARS” score (maximum total of 93 points5).
Psychometric properties of the FARSn and the mFARS
were recently summarized,5 but there remained a lack of
published information specifically on test–retest reliability
in these scales. In this study, we evaluated the test–retest
reliability in the mFARS and the FARSn scales using data
from recent clinical research in FRDA.

Material and Methods
Data source/ clinical studies
FARSn and mFARS scores were acquired from the FRDA
integrated clinical database (FA-ICD) maintained by the
Critical Path Institute (c-PATH). As of May 2020,
these data included screening and baseline visits from
the following clinical trials in FRDA: MICONOS
(NCT00905268), IONIA6 (NCT00537680), LA-297
(NCT00530127), and EPI-7438 (NCT01728064). For the
EPI-743 study and LA-29, the FA-ICD only included data
from the placebo arm. Additional data were provided
directly by sponsors: Reata Pharmaceuticals (MOXIe,
NCT02255435) and Chiesi Canada (additional predose
data from LA-29, NCT00530127). The scales analysed in
this study were the mFARS, FARSn, and FARSn-117. For
the test–retest analyses, we used all available data, as long
as full exam results from two visits (screening and baseline) were available.

Statistical analysis/ Test–Retest-Reliability
Testing took place during screening and baseline visits of
clinical trials, with the time between those visits generally
not considered to lead to a relevant clinical decline of the
condition. This was assessed by comparing means
between the two visits using paired t-test and calculating
the mean in-between change. In this specific situation,
every patient was administered two exams by the same
rater, allowing for assessment of the consistency between
the ratings, but not between rater-variability. We, therefore, used the one-way analysis of variance ANOVA-based
intraclass correlation coefficient (ICC2,1 by standard
nomenclature 9,10) to assess the test–retest reliability of
the FARS scales. Also, we calculated coefficients of variance (CV), the standard error of the measurement
(SEM), and the minimally detectable change at 90% confidence (MDC), reflecting the magnitude of change necessary in an individual to ensure that a change is not the
result of random variation or measurement error. Group
level MDC is usually of less interest due to sample size
calculations in clinical trials.11 The MDC was then
divided by the range of the individual measure to yield

mFARS ICC

the relative amount of the random measurement error
(MDC%). Bland-Altman plots were used to visualize the
difference and mean score of each pair of measurements.
All data derivation and analyses were conducted in R
(www.r-project.org) utilizing the psych-package12 for calculation of the ICCs.

Results
mFARS and FARSn test–retest data were available from
172 patients from the IONIA and MOXIE studies
(Table 1). Only in these studies did the neurological
exams include the two stance items performed with eyes
closed,5 necessary to calculate mFARS and FARSn. For
the remaining studies (EPI-743, LA-29, and MICONOS),
only FARSn-117 data were available. In addition, the EPI743 study only included one predose visit. Therefore, (excluding EPI-743) data from a total of 405 patients could
be evaluated for the test–retest analysis of FARSn-117.
Visit timing indicates values foreseen in study protocols
as exact dates were only on hand for the LA-29 study
(median time between visits was 42 d, range 26 d to 97d,
Table 1).
ICC values above 0.90 usually indicate excellent test–
retest reliability;13 the present results overall demonstrate
this for the mFARS scale with an ICC of 0.95 (95%CI
0.94–0.96). Mean values for both visits were 42.3 (SD
10.8) and 42.3 (SD 10.7), and the mean change was 0.1
(SD 3.3), showing that no relevant change in the scores
has occurred between the visits. ICC and other corresponding values for FARSn and the FARSn-117 confirm
these results (Table 2). All P-values from paired t-tests
were nonsignificant (i.e. larger than 0.05). The minimally
detectable change for mFARS was 5.51 points, which

Table 1. Summary of available data at screening and baseline visits.
Time from
Screening
to Baseline

N1

up to 1 month

103

within 8 weeks

69

EPI-743

mFARS
FARSn
FARSn-117
mFARS
FARSn
FARSn-117
FARSn-117

–

20

MICONOS
LA-29

FARSn-117
FARSn-117

within 8 weeks
less than
3 months

Study
MOXIE

IONIA

Scales
Evaluated

Comments

Study included
only 1 predose
visit.

161
72

1

Participants with full scale data from two visits available.
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Table 2. Test–Retest Reliability indices of mFARS scale.

Parameter
mFARS
FARSn
FARSn-117
Subscores
Bulbar
Upper Limbs
Lower Limbs
Upright Stability
Items (mFARS only)
A4 cough
A4 speech
B1 finger to finger
B2 nose to finger
B3 dysmetria
B4 rapid movements
B5 finger taps
C1 heel shin slide
C2 heel shin tap
E1 sitting position
E2A stance feet apart
E2B (eyes closed)
E3A stance feet
together
E3B (eyes closed)
E4 tandem stance
E5 stance dominant foot
E6 tandem walk
E7 gait

max. score

n

Mean (SD)
D1

Mean (SD)
D2

d

P*

ICC

95%CI

CV

SEM

MDC

MDC
(%)

93
125
117

172
172
405

42.3 (10.8)
52.2 (12.2)
48.1 (18.1)

42.3 (10.7)
52.2 (12)
48.1 (17.8)

0.1 (3.3)
0 (4.3)
0 (4.8)

0.956
0.995
0.969

0.95
0.94
0.96

(0.94–0.96)
(0.92–0.95)
(0.96–0.97)

5.57
5.75
6.99

2.36
3.02
3.39

5.51
7.05
7.91

6
6
7

5
36
16
36

172
172
172
172

0.7 (0.6)
12.6 (4.7)
7.1 (2.6)
21.9 (6.3)

0.8 (0.6)
12.5 (4.7)
7.2 (2.6)
21.8 (6.4)

0.1 (0.5)
0.1 (2.2)
0.1 (1.5)
0.1 (2)

0.251
0.806
0.790
0.892

0.73
0.89
0.83
0.95

(0.65–0.79)
(0.85–0.92)
(0.78–0.87)
(0.93–0.96)

42.89
12.57
15.07
6.48

0.33
1.58
1.07
1.40

0.77
3.68
2.49
3.26

15
10
16
9

2
3
6
8
8
6
8
8
8
4
4
4
4

172
172
172
172
172
172
172
172
172
172
172
172
172

0.1
0.6
1.5
2.3
2.8
2.9
3.1
4.2
2.9
0.7
0.6
2.8
1.9

(0.3)
(0.5)
(1)
(1)
(1.3)
(1.3)
(1.5)
(1.4)
(1.6)
(0.5)
(1.4)
(1.7)
(1.8)

0.1 (0.3)
0.7 (0.5)
1.6 (1.1)
2.2 (1.1)
2.7 (1.3)
3 (1.3)
3 (1.5)
4.1 (1.4)
3.1 (1.6)
0.8 (0.5)
0.6 (1.3)
2.8 (1.7)
1.9 (1.8)

0 (0.2)
0.1 (0.4)
0.1 (0.8)
0 (0.8)
0.1 (1)
0 (0.9)
0.1 (1.1)
0.1 (1.1)
0.1 (1)
0.1 (0.4)
0 (0.6)
0 (0.7)
0.1 (0.9)

0.705
0.226
0.439
0.782
0.447
0.837
0.519
0.677
0.419
0.362
0.989
0.924
0.797

0.75
0.65
0.72
0.70
0.68
0.76
0.72
0.72
0.80
0.64
0.90
0.91
0.87

(0.68–0.81)
(0.56–0.73)
(0.63–0.78)
(0.61–0.77)
(0.59–0.75)
(0.68–0.81)
(0.64–0.79)
(0.64–0.79)
(0.73–0.84)
(0.55–0.72)
(0.87–0.92)
(0.88–0.93)
(0.83–0.9)

129.30
45.71
36.97
26.17
26.81
21.99
25.92
18.19
24.09
41.88
71.62
18.61
34.55

0.14
0.29
0.56
0.57
0.76
0.66
0.80
0.76
0.73
0.32
0.43
0.52
0.65

0.33
0.68
1.30
1.32
1.78
1.55
1.88
1.78
1.71
0.75
1.00
1.22
1.52

16
23
22
17
22
26
23
22
21
19
25
30
38

4
4
4
3
5

172
172
172
172
172

3.9 (0.4)
3.6 (0.9)
3.9 (0.4)
2.4 (0.7)
2 (1.2)

3.9 (0.4)
3.4 (1.3)
3.9 (0.4)
2.4 (0.7)
2 (1.2)

0 (0.2)
0.2 (1)
0 (0.3)
0 (0.5)
0 (0.5)

0.734
0.104
0.772
0.708
0.895

0.89
0.60
0.82
0.75
0.92

(0.85–0.92)
(0.49–0.69)
(0.77–0.87)
(0.67–0.81)
(0.9–0.94)

3.61
20.15
4.65
15.21
16.61

0.13
0.60
0.18
0.37
0.34

0.31
1.39
0.41
0.87
0.80

8
35
10
29
16

*p-value for paired t-test comparing the means between both visits

corresponds to a percentage MDC of 6%, likewise an
excellent value.11,13
The mFARS subscores and, in particular, upright stability showed similar preferable results with ICCs of 0.95
(upright stability), 0.89 (upper limbs), 0.83 (lower limbs),
and 0.73 (bulbar). Among the individual items in the
scale, this ensures that the essential stance items (E2A,
E2B, and E3A), as well as the gait item, have excellent to
good ICCs.
A Bland-Altman plot for the assessments of mFARS
(Fig. 1) shows no clear trends for less reliability at any
mean scores. Outliers occurred both at low and at average
overall scores.

Discussion
The present study shows that the mFARS and FARS exams
have excellent test–retest properties as need for use in therapeutic trials and other clinical studies. The FARS was first
introduced in 20053 as a disease-specific clinical rating
instrument to capture functional abilities related to
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neurological aspects of FRDA. Further optimization and
focus on functional, patient relevant items, together with
psychometric analyses of the FARSn5 has further refined
this instrument to the “mFARS” score, which has been used
both as primary and secondary endpoint in contemporary
clinical trials of FRDA. Compared to the FARSn, the
mFARS appears less prone particularly to floor effects, and
shows a better dimensional structure, while retaining an
adequate level of internal consistency.5 While mild ceiling
effects are retained, particularly the gait subscore of the
mFARS was shown to captures well the progressive function loss associated with loss of ambulation in FRDA.14 The
results in the present work complement these features.
Validity of the FARS scales has been assessed in many
observational studies, demonstrating its high correlation
with age of onset, genetic burden of disease (GAA repeat
length), and patient reported outcome measures such as
the ADL scale.4,15,16 It also correlates with other rating
scales such as the Scale for the Assessment and Rating of
Ataxia (SARA) score, a modified version of Barthel Index,
and the Functional Independence measure.17,18 The
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Figure 1. Bland–Altman Plot for differences between screening and baseline visits in the mFARS scale.

mFARS/FARS associates not only with walking speed,
cadence, and stability indexes,19 but also with physiopathological aspects of the disease, including iron clustering at the cerebellum,20 atrophy in cerebellar peduncles,21,22 degeneration of the spinal cord,23 and FXN
expression.24 The FARSn and mFARS scales have shown
adequate internal consistency, and inter-rater reliability.3,5
Test–retest reliability however requires short-term follow-up data, which requires nontrivial efforts to obtain. In
this study, we filled this gap using data from recent clinical
studies and successfully proved the test–retest reliability of
the overall scale. This study demonstrated excellent test–
retest reliability of the mFARS, the FARSn, and the FARSn117 scores as well as the mFARS upright stability score. In
isolation, upper - and lowerlimb subscores still showed
good ICCs, while the bulbar subsection had a moderate
ICC. A potential limitation of the current study is the lack
of intraday retesting, although such testing could conceivably be associated with practice effects. In addition, the fatigability of FRDA patients could confound same day testing.
Also, in specific studies (e.g. LA-29) the between-test interval was fairly long, but the impact is considered low, given
the (relatively) slow progressive nature of the disease. Due
to the inherent variability of all FRDA patients, future clinical trials will likely focus on targeted subpopulations, and
further work hopefully will provide evidence that the

excellent overall qualities of the mFARS scale apply also to
these dedicated patient subgroups.
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